| abstract |
The present invention relates to tertiary butyl (7-methylimidazo [1,2-a] pyridin-3-yl) amine derivatives of formula (I) wherein R1 is hydrogen or straight or branched, unsubstituted or singly or multiply substituted alkanyl. ; and R 2 is C 1-8 straight or branched, saturated or unsubstituted or singly or multiply substituted alkyl; C3-C8 saturated or unsaturated, substituted or singly or multiply substituted cycloalkyl; saturated or unsaturated, unsubstituted or singly or multiply substituted heterocyclyl; unsubstituted or singly or multiply substituted aryl; unsubstituted or singly or multiply substituted heteroaryl; C 1 -C 8 alkyl (C 3 -C 8 cycloalkyl); C 1-8 alkyl heterocyclyl; C 1 -C 8 alkylaryl or C 1 -C 8 alkylheteroaryl; wherein the alkyl group may be linear or branched, saturated or unsaturated, and mono- or polysubstituted; the cycloalkyl group may be saturated or unsaturated and unsubstituted or mono- or polysubstituted; the heterocyclic group may be saturated or unsaturated and unsubstituted or mono- or polysubstituted; the aryl group is unsubstituted or mono- or polysubstituted and the aheteroaryl group is unsubstituted or mono- or polysubstituted] and their pharmaceutically acceptable salts, their preparation and pharmaceutical compositions containing them. The compounds of the present invention possess NO-synthase inhibitory activity and are useful inter alia in the treatment of migraine. SHE |